Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Autoimmune diseases are highly prevalent in humans, being characterized by early onset and high risks of disability, thus determining the relevance of the present work and its aim, i.e., studying metabolic characteristics of lymphocytes upon the adjuvant-induced autoimmune disorder in rats. Modeling of the autoimmune process was performed in Wistar rats by subcutaneous administration of a Freund’s complete adjuvant, i.e., water-oil emulsion with heat-killed M. tuberculosis. Hematology testing (complete blood counts), biochemical markers (hydroperoxides, malondialdehyde (MDA), catalase), and cytobiochemical changes in lymphocytes (lactate dehydrogenase, succinate dehydrogenase; LDH, SDH) were followed in dynamics. X-ray examination was performed at the end of the experiment. At the initial stage of autoimmune arthritis (2 weeks), leukocytosis was registered (26.12±2.30 × 109 /L, i.e., 65% over the controls, p < 0.01), thrombocytosis (675±30 × 109 /L, compared with 536±27 × 109 /L in controls, p < 0.01), and oxidative stress were also observed (hydroperoxides increased by 7%, and MDA, by 32%, p < 0.001); energy levels of the lymphocytes increased due to activation of LDH by 6.5%, and SDH, by 49% against the controls. At chronic stage of the disorder (7 weeks), the systemic inflammation was milder (total WBC counts of 19.6±1.40 × 109 /L, compared with 13.68±0.86 × 109 /L in controls, p < 0.01, associated with shift to the right in differential conuts), along with persisting oxidative stress (MDA exceeds the control levels by 37%; decrease in catalase activity), and lower LDH activity in lymphocytes (by 43%, p < 0.01) associated by their decrease in size (the correlation quotient between the lymphocyte radius and LDH activity is rxy = 0.87). Profound molecular changes were observed in the cell energy supply: the respiratory quotient for control animals (LDH/SDH ratio) varied within 4.6-5.0. Meanwhile, in autoimmune animals, metabolic contribution of glycolysis showed a significant decrease (the quotient of 3.2 by the 2nd week, and 2.4 by the 7th week). On the radiograph by 7th week, the experimental animals show uneven joint space narrowing, cyst-like formations and subchondral sclerosis of the bone heads. Autoimmune rheumatoid arthritis in rats is characterized by metabolic disorders of lymphocytes manifesting as general energy deficiency, and imbalance between glycolysis and oxidative phosphorylation pathways. These findings allow of deeper insight into pathogenesis and suggesting further search for molecular targeted therapy and prevention of the disease.
Autoimmune diseases are highly prevalent in humans, being characterized by early onset and high risks of disability, thus determining the relevance of the present work and its aim, i.e., studying metabolic characteristics of lymphocytes upon the adjuvant-induced autoimmune disorder in rats. Modeling of the autoimmune process was performed in Wistar rats by subcutaneous administration of a Freund’s complete adjuvant, i.e., water-oil emulsion with heat-killed M. tuberculosis. Hematology testing (complete blood counts), biochemical markers (hydroperoxides, malondialdehyde (MDA), catalase), and cytobiochemical changes in lymphocytes (lactate dehydrogenase, succinate dehydrogenase; LDH, SDH) were followed in dynamics. X-ray examination was performed at the end of the experiment. At the initial stage of autoimmune arthritis (2 weeks), leukocytosis was registered (26.12±2.30 × 109 /L, i.e., 65% over the controls, p < 0.01), thrombocytosis (675±30 × 109 /L, compared with 536±27 × 109 /L in controls, p < 0.01), and oxidative stress were also observed (hydroperoxides increased by 7%, and MDA, by 32%, p < 0.001); energy levels of the lymphocytes increased due to activation of LDH by 6.5%, and SDH, by 49% against the controls. At chronic stage of the disorder (7 weeks), the systemic inflammation was milder (total WBC counts of 19.6±1.40 × 109 /L, compared with 13.68±0.86 × 109 /L in controls, p < 0.01, associated with shift to the right in differential conuts), along with persisting oxidative stress (MDA exceeds the control levels by 37%; decrease in catalase activity), and lower LDH activity in lymphocytes (by 43%, p < 0.01) associated by their decrease in size (the correlation quotient between the lymphocyte radius and LDH activity is rxy = 0.87). Profound molecular changes were observed in the cell energy supply: the respiratory quotient for control animals (LDH/SDH ratio) varied within 4.6-5.0. Meanwhile, in autoimmune animals, metabolic contribution of glycolysis showed a significant decrease (the quotient of 3.2 by the 2nd week, and 2.4 by the 7th week). On the radiograph by 7th week, the experimental animals show uneven joint space narrowing, cyst-like formations and subchondral sclerosis of the bone heads. Autoimmune rheumatoid arthritis in rats is characterized by metabolic disorders of lymphocytes manifesting as general energy deficiency, and imbalance between glycolysis and oxidative phosphorylation pathways. These findings allow of deeper insight into pathogenesis and suggesting further search for molecular targeted therapy and prevention of the disease.
Currently, the problem of persistent myocardial damage in patients who have had COVID-19 has become one of the most pressing in the practice of cardiologists. The main mechanisms of the pathogenesis of post-COVID myocarditis are associated with a violation of immunoregulation caused by long-term persistence of the virus in the heart muscle and the launch of autoimmune processes that can lead to myocardial remodeling, the formation of myocardiosclerosis and the development of heart failure or arrhythmia. The purpose of this study was to assess the dynamics of the production of certain cytokines (IFNg, IL-4, IL-17А), which may indirectly reflect the activation of various immune response pathways in patients with post-COVID myocarditis, depending on the duration of the disease and the degree of heart failure. The study included 32 patients with post-COVID myocarditis, 36 patients with myocardial cardiosclerosis, and 10 apparently healthy individuals. It was found that in all patients with post-COVID myocarditis, the content of IFNg, IL-4, IL-17А in the blood serum was higher than in patients with myocardial cardiosclerosis (p 0.001; p 0.05; p 0.01, respectively) and conditionally healthy individuals (p 0.001; p 0.01; p 0.001, respectively). Compared with the group of patients with no or moderate severity of symptoms of heart failure (functional class 0–II), those with more severe heart failure (functional class III) had a higher level of interferon gamma (p 0.05). When comparing the results obtained with similar indicators in patients with myocardial cardiosclerosis who have the same degree of heart failure, no statistically significant differences were obtained. The maximum content of IFNg in post-COVID myocarditis was observed in the 2nd week of the disease (p 0.001 compared with the control group); then its level gradually decreased and by the end of the 2nd month there were no longer any significant differences. The opposite trend was observed in relation to the content of IL-4 and IL-17А: in the first two weeks, no statistically significant differences were detected with the control group, but then their content increased quite quickly (p 0.001 compared with the control group by the end of the first month of the disease) and continued to remain the same high until the end of the 2nd month. Thus, monitoring the content of IFNg, IL-4, IL-17А in blood serum can to some extent provide an idea of the sequence of development of the immune response in post-COVID myocarditis. An increase in IFNg levels in the early stages of the disease is probably associated with an increase in the manifestations of heart failure. Th17-mediated mechanisms may be involved in the process of myocardial remodeling resulting in myocardial cardiosclerosis.
A significant part of the complications of COVID-19 and manifestations of post-COVID syndrome is associated with autoimmune reactions caused by SARS-CoV-2. The key mechanism for the implementation of autoimmunity in COVID-19 is molecular mimicry, which is involved in the development of a cytokine storm, systemic multiorgan hyperinflammation, endothelial dysfunction, and is also a trigger for the development of autoimmune diseases (autoimmune thrombocytopenia, autoimmune vasculitis, Guillain-Barr syndrome, Miller-Fisher syndrome, autoimmune neuropathy, autoimmune thyroiditis, rheumatoid arthritis and others) after COVID-19. In total, 59 common immune determinants were identified in 80 epitopes of the SARS-CoV-2 spike protein with 53 anti-inflammatory proteins, receptors that regulate cell proliferation, differentiation and apoptosis, as well as the immune response. It was found that among the 37 proteins of the virus, only 8 do not have immunogenic regions identical to human proteins. Cross-reactivity leads to the formation of more than 15 distinct types of autoantibodies, including antiphospholipid antibodies to cardiolipin and beta2-glycoprotein I, antibodies to the transmembrane adenosine receptor A2b, adiponectin, phosphatidylserine-prothrombin autoantibodies, antinuclear antibodies, antibodies to mitochondrial M2, autoantibodies against type I interferons, and other cytokines, chemokines, complement components and cell membrane proteins. Autoantibodies formed during COVID-19 react with antigens of cells of the thyroid gland, cardiac and skeletal muscles, lung, joints, liver, kidneys, brain and bone marrow, peripheral nervous system, skin and adipose tissue, gastrointestinal tract, testicles, eyes, and also with mitochondrial antigens, mediating the development of severe complications of the disease and the development of post-covid syndrome. The presence of 24 homologous pentapeptides with Bordetella pertussis, C. diphtheriae, C. tetani, H. influenzae and N. Meningitides provokes the risk of developing an ineffective immune response to vaccination against the background of an increased risk of autoimmune complications. It is imperative to take into account the phenomenon of molecular mimicry in the development of new approaches to the rehabilitation and treatment of COVID-19, as well as in the development and testing of vaccines against SARS-CoV-2.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.